DRUG CARRIER SYSTEMS OF CHEMOTHERAPEUTIC DRUGS: RADIOLABELED CYCLOPHOSPHAMIDE LOADED MESOPOROUS SILICA NANOPARTICLES
Project no. 20684 · Status: Kapanmış (Yayın bekleniyor) · 2019
Summary
Silica nanoparticles are used in various applications in the field of health thanks to their properties such as biocompatibility and low toxicity. Thanks to their porous structure, mesopore silica nanoparticles (MSN) make it easier to load the drug into the system and deliver it to the target area in a controlled manner. In this study, it was aimed to synthesize cyclophosphamide (CPH) loaded mesoporous silica nanoparticles, radiolabeled with technetium-99m and analyze the biological behavior of this structure in vitro. Optimum conditions were determined by examining parameters such as particle size, morphology, drug entrapment capacity of synthesized nanoparticles. The characterization of nanoparticles was carried out by Fourier Transform Infrared Spectroscopy (FTIR), Dynamic Light Scattering (DLS), Scanning electron microscopy (SEM). The synthesized MSNs have a hydrodynamic radius of 125 ± 3.4 nm according to DLS analysis. SEM images showed that nanoparticles have a spherical morphological structure and distributed between 55 and 70 nm in size. Quality control studies of radiolabeled Cyclophosphamide loaded mesopore silica nanoparticles (99mTc-MSN-CPH) were carried out using Thin Layer Radiochromatography (TLRC) method. MSN-CPH nanoparticles were successfully radiolabeled with technetium-99m in 99.82 ± 0.25% efficiency. After quality control studies, cytotoxicity and uptake studies of cyclophosphamide-loaded mesopore silica nanoparticles were performed in vitro using MCF-7 and MDA-MB-231 breast cancer cells. It was found that 99mTc- MSN-CPH particles showed similar uptake in MCF7 and MDA-MB-231 cells. It is thought that the nanostructure synthesized in this thesis will contribute to the development of new generation radiolabeled nanoteranostic systems with 99mTc that can be used in the diagnosis and treatment of cancer in the future.